Tripterine nano particle as well as preparation method and application thereof
The tributary ferric iron nanoparticles prepared by combining tripletrin with water-soluble polymers of iron ions and dopamine groups have solved the solubility and toxicity of tripletrin in clinical applications, and achieved tumor remedy Selective killing of cells provides new nano-anti-cancer drug delivery protocols.
Patent Information
- Application Number
- CN202411077745.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing tributary elutin nanodelivery system has low water solubility, poor permeability, reduced oral bioavailability and high organ toxicity problems in clinical applications, and the cytotoxicity and killing properties prepared by traditional methods are not ideal, which is difficult to Effectively used in clinical treatment.
Responsively released triplet iron nanoparticles were prepared by mixing triplet lutin with iron ions to form triplet lutin-iron complexes and combining them with water-soluble polymers containing dopamine groups. (CeFeNPs) release Cel-Fe complexes in a weakly acidic environment, dissociate and release Cel and Fe3+ using ATP competition, promote lipid peroxidation and induce tumor cell death.
Successfully improves the water solubility and stability of triplet lipocin, reduces toxicity, enhances its therapeutic function, realizes selective killing of tumor cells, provides a new nano-anti-cancer drug delivery system and targeted anti-tumor drugs Application ideas.
Smart Images

Figure CN118903018A_ABST
Abstract
Description
Technical Field
[0001] The present invention generally relates to the technical field of nano-biomaterials, and in particular to a tripterygium wilfordii nanoparticle and a preparation method and application thereof. Background Art
[0002] Celastrol (Cel) is a Tripterygium wilfordii extract, and several studies have demonstrated its pharmacological activity and mechanism of action against various diseases, including cancer, inflammation, autoimmunity, neurodegenerative diseases, and obesity. In the field of tumor treatment, Celastrol has shown significant anti-cancer activity. The drug induces autophagy by interfering with the PI3K / Akt / mTOR pathway and promoting G2 / M phase cell cycle arrest, and inhibits the survival and proliferation of cancer cells through this mechanism. In addition, Celastrol can also promote endoplasmic reticulum stress and the resulting programmed cell death, which is crucial for restoring protein homeostasis in the tumor microenvironment.
[0003] Although the anticancer activity and mechanism of Cel have been extensively studied, current research cannot solve the problems in its clinical use. The main limitations it faces include low water solubility, poor permeability, reduced oral bioavailability, and high organ toxicity that may be induced in the heart, liver, and nervous system. To overcome these limitations, researchers are exploring a variety of delivery strategies including chemical modification and nanotechnology.
[0004] Applying nanosystems to Cel delivery can effectively address challenges in clinical applications. Nanotechnology-based carriers such as human serum albumin, liposomes, and exosomes have been shown to have many advantages. For Cel's nanodelivery system, its advantages include: better improvement of drug solubility and oral bioavailability; the sustained release effect of nanoparticles prolongs the retention time of drugs in the blood; encapsulating Cel in a micro-nano system can change its pharmacokinetic characteristics, and the passive targeting effect brought about by the size effect can make it more conducive to passing through the incomplete vascular wall of the tumor site, with a targeted drug delivery effect, while improving Cel's ability to kill tumor cells and reducing organ toxicity. In summary, the nanodelivery system has the potential to improve Cel's in vivo bioavailability and reduce drug toxicity.
[0005] Traditional Cel nano-delivery systems mostly use hydrophobic forces to encapsulate drugs in the system. The drug encapsulation rate is limited, and it can also lead to non-specific drug leakage during the delivery process, causing non-specific killing of normal cells, and it is more likely to produce batch differences in nanoparticles during the multi-step synthesis reaction process.
[0006] Chinese invention patent ZL202211076229.4, filed on September 2, 2022, discloses a method for preparing a tripterygium wilfordii iron complex. However, the cytotoxicity and lethality of the complex prepared by this method are not ideal, and it cannot be effectively used in clinical treatment. Summary of the invention
[0007] The present invention covers the following technical solutions: According to one aspect of the present invention, the present invention relates to a method for preparing tripterygium wilfordii nanoparticles (CeFeNPs), comprising: a) mixing a Celastrol (Cel) solution and an iron ion solution to obtain a Celastrol-iron complex (Cel-Fe); b) mixing the tripterygium wilfordii-iron complex with a water-soluble high molecular polymer containing a dopamine group in a molar ratio of 1:(1-2) to obtain an organic phase solution; c) uniformly dispersing the organic phase solution in water to obtain a mixed solution; d) dialyzing the mixed solution and then performing solid-liquid separation to obtain a solid component.
[0008] According to yet another aspect of the present invention, the present invention also relates to tripterygium wilfordii nanoparticles, which are prepared by the method as described above.
[0009] According to another aspect of the present invention, the present invention also relates to a pharmaceutical composition, which contains the tripterygium wilfordii nanoparticles as described above and a pharmaceutically acceptable carrier.
[0010] According to another aspect of the present invention, the present invention also relates to the use of the tripterygium wilfordii nanoparticles as described above in the preparation of a medicament for treating tripterygium wilfordii-responsive diseases or conditions; the tripterygium wilfordii-responsive diseases or conditions include any one or more of the following: cancer, inflammatory and / or autoimmune disorders, neurological disorders, obesity-related diseases or conditions, liver-related diseases or conditions, and eye disorders or injuries.
[0011] The beneficial effects of the present invention are: (1) The present invention successfully synthesized celastrol iron nanoparticles (CeFeNPs), which are expected to enhance the functionality of celastrol in the in vivo therapeutic process by increasing the water solubility and stability of celastrol and reducing its toxicity.
[0012] (2) CeFeNPs are responsive release particles that can first release Cel-Fe complexes in a weakly acidic environment, and then dissociate and release Cel and ATP-Fe under the competitive action of high concentrations of ATP in the tumor microenvironment. 3+It is beneficial to produce reactive oxygen species through the Fenton reaction, thereby further promoting lipid peroxidation and inducing ferroptosis of tumor cells, and ultimately exerting an anti-cancer effect by inhibiting tumor cell proliferation and promoting apoptosis.
[0013] (3) CeFeNPs unexpectedly exhibited a relatively obvious selective killing effect on tumor cells and normal cells, which provided new ideas for the development of nano anticancer drug delivery systems and targeted antitumor drug applications. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0015] Figure 1 DLS particle size test results of CeFeNPs; Figure 2 is the transmission electron microscopy image of CeFeNPs; Figure 3 is the experimental result of CeFeNPs stability; Figure 4 The re-dissolved particle size and physical picture of CeFeNPs; Figure 5 Results of in vitro simulated release experiments of CeFeNPs; Figure 6 The results are for 4T1 cell cytotoxicity experiments; Figure 7 The results of flow cytometry for cell apoptosis; Figure 8 The results of 4T1 and 3T3 cell toxicity experiments are shown; Fig. 9 The results are for 4T1-GFP and 3T3-RFP cell killing; Fig.10 The results of the AAS test for iron content; Fig.11 To detect the cellular uptake of Cy5.5 CeFeNPs by CLSM; Fig.12 Results of intracellular ROS detection by CLSM. DETAILED DESCRIPTION
[0016] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.
[0017] Unless otherwise indicated, the meaning of all terms (including technical and scientific terms) used to disclose the present invention is the same as that commonly understood by those of ordinary skill in the art to which the present invention belongs. By way of further guidance, the following definitions are used to better understand the teachings of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.
[0018] In the present disclosure, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology and laboratory operation procedures used herein are terms and routine procedures widely used in the corresponding fields. At the same time, in order to better understand the present disclosure, the definitions and explanations of the relevant terms are provided below.
[0019] The terms "and / or", "or / and", and "and / or" used herein include any one of two or more related listed items, and also include any and all combinations of related listed items, wherein the any and all combinations include any combination of two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in the present invention, the technical solution undoubtedly includes technical solutions connected by "logical and", and undoubtedly includes technical solutions connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").
[0020] As used herein, the terms "comprising", "including" and "comprising" are synonymous and are inclusive or open-ended and do not exclude additional, unrecited members, elements or method steps.
[0021] Numerical ranges expressed as endpoints herein include all numbers and fractions subsumed within the range, as well as the recited endpoints.
[0022] As used herein, reference to "about" a value or parameter includes (and describes) embodiments directed to the value or parameter itself. For example, description referring to "about X" includes description of "X".
[0023] The present invention relates to concentration values, and the meaning includes fluctuations within a certain range. For example, it can fluctuate within a corresponding precision range. For example, 2%, it is allowed to fluctuate within ±0.1%. For values that are large or do not require too fine control, it is also allowed to have a greater fluctuation. For example, 100mM, it is allowed to fluctuate within the range of ±1%, ±2%, ±5%, etc. Involving molecular weight, it is allowed to have a fluctuation of ±10%.
[0024] As used herein, the singular articles "a," "an," and "the" include plural referents unless otherwise indicated.
[0025] In the present invention, descriptions such as "plurality" and "multiple" refer to quantities greater than or equal to 2 unless otherwise specified.
[0026] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0027] In the present invention, "preferably", "better", "more preferably", and "suitably" are only used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute a limitation on the scope of protection of the present invention. In the present invention, "optionally", "optional", and "optional" refer to being optional, that is, any one of the two parallel schemes of "yes" or "no". If multiple "options" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent of each other.
[0028] All documents mentioned in the present invention are cited as references in the present invention, just as each document is cited as a reference separately. Unless they conflict with the invention purpose and / or technical solution of the present invention, the cited documents involved in the present invention are cited with all contents and all purposes. When the present invention involves cited documents, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When the present invention involves cited documents, the examples and preferred embodiments of the cited relevant technical features can also be incorporated into the present invention as references, but are limited to the ability to implement the present invention. It should be understood that when the cited content conflicts with the description in the present invention, the present invention shall prevail or be modified adaptively according to the description of the present invention.
[0029] The present invention relates to a method for preparing tripterygium wilfordii nanoparticles, which comprises: a) mixing a tripterygium wilfordii solution and an iron ion solution to obtain a tripterygium wilfordii-iron complex; b) mixing the tripterygium wilfordii-iron complex with a water-soluble high molecular polymer containing a dopamine group in a molar ratio of 1:(1-2) to obtain an organic phase solution; c) uniformly dispersing the organic phase solution in water to obtain a mixed solution; d) dialyzing the mixed solution and then performing solid-liquid separation to obtain a solid component.
[0030] The tripterygium wilfordii used in the present invention is preferably (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid.
[0031] According to the inventor's verification, the dopamine group and the tripterygium wilfordii-iron complex have a strong coordination effect, so that suitable tripterygium wilfordii nanoparticles can be formed. Other water-soluble polymers such as polyvinyl pyrrolidone PVP, polyacrylic acid and other structures cannot form tripterygium wilfordii nanoparticles with tripterygium wilfordii nanoparticles due to their weak coordination ability, or the formed nano-ions are not ideal. In some embodiments, the water-soluble high molecular polymer containing a dopamine group is methoxy polyethylene glycol dopamine (mPEG-DOPA).
[0032] mPEG-DOPA can be of various molecular weight distributions, but preferably, the molecular weight of the methoxypolyethylene glycol dopamine is 2000-5000, such as mPEG-DOPA2000, mPEG-DOPA3400, and mPEG-DOPA5000.
[0033] In step a), the iron ions are in excess relative to tripterygium wilfordii. Preferably, the molar ratio of tripterygium wilfordii in the tripterygium wilfordii solution to the iron ions in the iron ion solution is 1:(1-2).
[0034] In step a), the preparation method of mixing the tripterygium wilfordii solution and the iron ion solution is well known. For example, the solvent used in the tripterygium wilfordii solution is an organic solvent; the organic solvent used may include but is not limited to dichloromethane, methanol, dimethyl sulfoxide, ethanol, acetone, chloroform and other organic solvents that can dissolve tripterygium wilfordii. For example, the solvent used in the iron ion solution is water.
[0035] An exemplary method of step a) is: slowly drop the iron ion solution into the tripterygium wilfordii solution, mix thoroughly and let stand for 3-7 minutes.
[0036] Step a) can adopt the method provided by the prior art as an example, such as the method described in Chinese invention patent ZL202211076229.4.
[0037] The iron ion in the present invention can be a trivalent or divalent iron ion, preferably a trivalent iron ion.
[0038] Iron ions can be obtained by dissolving soluble iron salts and their crystalline hydrates.
[0039] The mixing or dispersing method adopted in the present invention may be selected from stirring, vortexing, ultrasound and the like or a combination thereof. The solid-liquid separation method adopted in the present invention may be selected from evaporation, distillation, centrifugation, filtration and the like or a combination thereof. Preferably, the solid-liquid separation method in step d) is first centrifugation and then filtration; the centrifugal speed may be 3000r / min-4000r / min; and the filtration pore size may be 0.4μm-0.5μm.
[0040] In some embodiments, in step c), the volume of water is 10-50 times, or 15-25 times, such as 16, 17, 18, 19, 20, 21, 22, 23, 24, 30, 35, or 40 times that of the organic phase solution.
[0041] In step c), the water may be distilled water, deionized water or reverse osmosis water.
[0042] In step d), the water used for dialysis can be distilled water, deionized water, or reverse osmosis water.
[0043] In some embodiments, in step c), ultrasound and stirring are used to achieve uniform dispersion.
[0044] In some embodiments, the ultrasonic power is 60W-90W (eg, 65W, 70W, 75W, 80W, 85W), and the ultrasonic time is 1 min-3 min (eg, 2 min).
[0045] In some embodiments, the preparation method further comprises step e): freeze-drying the solid component obtained in step d).
[0046] The present invention also relates to a kind of tripterygium wilfordii nanoparticles, which are prepared by the method as described above.
[0047] According to yet another aspect of the present invention, there is also provided a pharmaceutical composition comprising the above-mentioned tripterygium wilfordii nanoparticles and a pharmaceutically acceptable carrier.
[0048] The definition of "pharmaceutically acceptable" as described herein refers to compounds, materials, complexes or dosage forms that are suitable for contact with human and animal tissues within the scope of reasonable medical judgment, and do not have excessive toxicity, irritation, allergic reactions and other problems. The term can also be replaced by "pharmaceutically acceptable".
[0049] The term "pharmaceutically acceptable carrier" as used herein refers to a pharmaceutically acceptable material, ingredient or vehicle, such as a liquid or solid filler, diluent, excipient, solution or coating material. Each carrier must be "acceptable" in terms of compatibility with another form of pharmaceutical formulation and not harmful to the patient. The following materials can be used as pharmaceutically acceptable carriers, including (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) astragalus powder; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as viscose fiber and suppository wax; (9) oils, such as peanut oil, cotton oil, sunflower oil, sesame oil, olive oil, carob oil; (10 ) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol (mannitol), mannan; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer and (21) other types of non-toxic compatible substances used in pharmaceutical preparations.
[0050] Pharmaceutically acceptable carriers can include physiologically acceptable agents to improve stability, increase solubility or increase the absorptive capacity of the nanoparticles of the present invention. Pharmaceutically acceptable carriers, including the selection of physiologically acceptable agents, depend on the mode of administration of the agents. The preparation of the preparation or the pharmaceutical combination can be a self-emulsifying drug delivery system or a self-microemulsifying drug delivery system. The pharmaceutical combination (preparation) can also be a liposome or other polymer matrix, and the nanoparticle or conjugate is incorporated therein. For example, liposomes or other lipid-composition liposomes are nontoxic, biocompatible, metabolizable carriers, and are easy to prepare and use.
[0051] The pharmaceutical composition can be administered by any of a variety of routes of administration, including oral administration (e.g., dissolved in water or non-aqueous solution or suspension, tablets, capsules, including micro-pellet capsules and gel capsules, pills, powders, granular preparations, adhesives) and parenteral administration. "Parenteral administration" as described herein refers to other modes of administration other than enteral and topical administration, usually by injection, including but not limited to intravenous, intramuscular, intercostal, interthecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intravertebral, intrasternal injection and infusion. Pharmaceutical ingredients suitable for parenteral administration include nanoparticles that are pharmaceutically usable aseptic isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, sterile powders, and their composition may be the same as sterile injections or dispersions. The pharmaceutical ingredients may include sterilizing agents, buffers, antibacterial agents, solutes that can be mixed with the blood of the intended subject, suspending agents, thickeners, or isotonic solutions.
[0052] According to yet another aspect of the present invention, it also relates to the use of the tripterygium wilfordii nanoparticles as described above in the preparation of a drug for treating tripterygium wilfordii-responsive diseases or disorders.
[0053] In some embodiments, the tripterygium wilfordii nanoparticles are combined with ATP to prepare a drug.
[0054] According to yet another aspect of the present invention, there is also provided a method for treating a tripterygium wilfordii responsive disease or disorder, comprising administering to a patient a therapeutically effective amount of the tripterygium wilfordii nanoparticles or pharmaceutical composition as described above.
[0055] In some embodiments, a therapeutically effective amount of ATP is also administered to release tripterygium wilfordii and iron.
[0056] Celastrol responsive diseases or conditions have been widely disclosed in the prior art and are known to those skilled in the art. In some embodiments, the celastrol responsive disease or condition includes any one or more of the following: cancer, inflammatory and / or autoimmune disorders, neurological disorders, obesity-related diseases or conditions, liver-related diseases or conditions, brain-related injuries or conditions, eye disorders or injuries.
[0057] In at least one embodiment of the above-mentioned uses or methods, the tripterygium wilfordii responsive disease or condition suffered by the subject may be cancer. Cancer may include, but is not limited to, gastric cancer, multiple myeloma, melanoma, leukemia, lymphoma, renal cell carcinoma, hepatocellular carcinoma, breast cancer, prostate cancer, head and neck cancer, non-small cell lung cancer, brain cancer and glioblastoma multiforme (GBM).
[0058] In at least one embodiment of the above-mentioned uses or methods, the tripterygium wilfordii responsive disease or condition suffered by the subject may be an inflammatory and / or autoimmune condition. Inflammatory and / or autoimmune conditions may include, but are not limited to, rheumatoid arthritis (RA), ankylosing spondylitis, systemic lupus erythematosus (SLE), inflammatory bowel disease, osteoarthritis (OA), allergies, and skin inflammation.
[0059] In at least one embodiment of the above uses or methods, the tripterygium wilfordii responsive disease or disorder suffered by the subject may be a neurological disorder. Neurological diseases may include, but are not limited to, Parkinson's disease, Huntington's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
[0060] In at least one embodiment of the above-mentioned uses or methods, the tripterygium wilfordii responsive disease or condition suffered by the subject may be an obesity-related disease or condition. The obesity-related disease or condition may include, but is not limited to, obesity, pre-obesity, morbid obesity, type 2 diabetes, atherosclerosis, diabetic nephropathy, gout, cardiac fibrosis, Prader-Willi syndrome, obesity associated with hypothalamic damage, non-alcoholic steatohepatitis, hyperlipidemia, hypertension, diabetes, lipodystrophy, fatty liver, Bardet-Biedl syndrome, Cohen syndrome, cardiovascular disease, arthritis, stroke, metabolic syndrome and MOMO (massive obese macrocephaly eye abnormality) syndrome.
[0061] In at least one embodiment of the above-mentioned uses or methods, the tripterygium wilfordii responsive disease or disorder suffered by the subject may be a liver-related disease or disorder. Liver-related diseases or disorders may include, but are not limited to, acute-chronic liver failure (ACLF), alcoholic liver disease, cholestatic liver disease, drug-induced liver disease, hepatocellular carcinoma, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), viral hepatitis, and viral liver disease.
[0062] In at least one embodiment of the above-mentioned uses or methods, the tripterygium wilfordii responsive disease or disorder suffered by the subject may be a brain-related injury or disorder. Brain-related injuries or disorders may include, but are not limited to, brain injury induced by middle cerebral artery occlusion (MCAO), cerebral ischemia / reperfusion (I / R) injury, vascular dementia (VD), and acute ischemic stroke-induced brain injury.
[0063] In at least one embodiment of the above-mentioned uses or methods, the tripterygium wilfordii responsive disease or condition suffered by the subject may be an ocular condition or injury. Ocular conditions or injuries may include, but are not limited to, dry eye disease, ocular inflammation, age-related macular degeneration (AMD), subconjunctival fibrosis, ocular hypertension-induced retinal degeneration, bright light-induced degeneration, macrophage-induced corneal neovascularization, corneal allograft survival, and optic nerve fragmentation.
[0064] Generally, a therapeutically effective amount is an amount sufficient to achieve the desired therapeutic purpose for the administered drug relative to the absence of the drug. For example, a therapeutically effective amount can be an amount that is determined to be sufficient to contribute to the treatment, prevention or alleviation of one or more symptoms of a disease. The method for determining the dosage of a drug providing a therapeutically effective amount is well known to those of ordinary skill in the art, and is generally based on the analysis of the amount determined in cell assays and / or animal models. For example, the dosage for administration to a person can be formulated to achieve a concentration that has been observed to be therapeutically effective in an animal model. The dosage in a pharmaceutical composition for a person can also be regulated by monitoring effectiveness and adjusting upward or downward.
[0065] The patient receiving the drug treatment of the present invention can be any animal in need, including primates, especially humans, and other mammals, such as horses, cattle, pigs, sheep, cats and dogs, poultry, and pets.
[0066] If desired, an effective daily dose of nanoparticles can be administered once, twice, three times, four times, five times, six times or more a day at intervals throughout the day, or alternatively, in a single dose.
[0067] In certain embodiments, the nanoparticles described herein can be used alone or co-administered with other types of therapeutic drugs.
[0068] Embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are preferably referred to the guidance provided in the present invention, and can also be based on the experimental manual or normal conditions in this area, and can also be based on other experimental methods known in the art, or according to the conditions recommended by the manufacturer.
[0069] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.
[0070] Example 1 - Preparation and Characterization of CeFeNPs Nanoparticles (1) Preparation of Cel-Fe complex solution I. Celastrol (Cel) ((2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid) was added into a reactor and dissolved with an organic solvent to obtain a solution A; The dissolution process was carried out at room temperature and was accelerated by magnetic stirring.
[0071] II. dissolving the iron salt in a solvent to obtain a solution B; The iron-containing salt used is ferric iron hydrochloride and its crystalline hydrate.
[0072] The solvent used was double distilled water.
[0073] The dissolution process is carried out at room temperature and is accelerated by magnetic stirring or the like.
[0074] III. Slowly add solution B to solution A, mix thoroughly, and let stand for 5 min to obtain Cel-Fe complex; The molar ratio of iron ions to Cel in solution A and solution B is 2:1, ensuring an excess of metal ions.
[0075] The dropwise mixing process is carried out at room temperature and can be accelerated by magnetic stirring, vortexing, ultrasound, etc.
[0076] (2) Add mPEG-DOPA5000 (50 mg) to the Cel-Fe complex solution (4.5 mg Cel) and mix thoroughly by ultrasonication to obtain 0.5 mL of organic phase solution; inject the organic phase solution into deionized water (10 ml) under ultrasonication at room temperature; After the addition was completed, the solution was ultrasonically treated and stirred for half an hour. To ensure that the particle size met the preparation requirements, the time for the organic phase solution to be injected into the deionized water solution was controlled at 3.0 s. The ultrasonic power was 75 W and the ultrasonic time was 2 min.
[0077] The liquid was then transferred to a dialysis bag with a MWCO of 3500 and dialyzed in deionized water for 3 days, with the water being changed every 8 hours; the liquid was then centrifuged (3500 r / min) and filtered (0.45 μm) to obtain CeFeNPs nanoparticles.
[0078] The encapsulation rate of Cel-Fe in the nanoparticles (i.e., the actual loading rate of Cel-Fe) was 70.0% as measured by Lambda 1050+ (Perkin Elmer, USA) UV-visible absorption spectroscopy. The particle size of the obtained nanomaterials was measured by dynamic light scattering (DLS). Figure 1 As shown, it is 84 nm; the morphology of the nanomaterial was characterized by transmission electron microscopy (TEM), and the results are shown Figure 2 As shown in Figure 3, the prepared nanomaterial is a spherical nanostructure. 100 μL of nanoparticle solution was added to 900 μL of double distilled water, PBS, cell culture medium, and FBS, and the particle size changes were detected for 5 consecutive days. The results are shown in Figure 3. In the same solution, the particle size of the nanoparticles remained consistent.
[0079] The CeFeNPs nanoparticles were placed in a freeze dryer for 24 h to obtain CeFeNPs freeze-dried powder, which was reconstituted with double distilled water and diluted 10 times. DLS measured that the particle size remained almost unchanged, and photos were taken as shown in the figure. Figure 4 As shown, the color of CeFeNPs is still dark green.
[0080] The above experiments prove that CeFeNPs have stable physical and chemical properties and iron ions are successfully loaded in the nanoparticles.
[0081] Example 2 - CeFeNPs nanoparticle responsive release The responsive release of CeFeNPs nanoparticles was detected by reading the UV-visible absorption spectrum with an enzyme-labeled instrument. At room temperature and in the dark, 1 mL of CeFeNPs solution was placed in an EP tube, and four experimental groups were set up, namely pH = 7.4, pH = 6.5, pH = 7.4 and 10 mM ATP, and pH = 6.5 and 10 mM ATP. 100 μL of solution was taken at 0, 0.5, 1, 2, 4, 8, 12, and 24 hours to read the absorbance of the detection well at 425 nm (peak absorbance). The test results are shown in Figure 2. Figure 5 As shown, with pH = 7.4 as the control, the release rate of the two experimental groups with ATP added at 24 h reached more than 50%, and the color was observed to become significantly lighter.
[0082] Example 3 - Effect of CeFeNPs on the Viability of Breast Cancer Cells 4T1 The MTT method was used to detect the activity of breast cancer cell 4T1 by CeFeNPs. The cells were seeded in 96-well plates at a density of 5000 cells per well and cultured for 12 h. The cells were incubated with Fe at final concentrations of 0.001, 0.01, 0.1, 1, 2, 4, 6, 8, 10, and 20 μM. 3+, Cel, Cel-Fe and CeFeNPs were incubated for 24 h. Then, 10% MTT diluted with RPMI 1640 (100 μL) was added to the wells. After incubation at 37°C, 5% CO2 for 4 h, 100 μL 10% SDS was added to each well and incubated at 37°C, 5% CO2 for 12 h. The absorbance of the wells was detected at 570 nm (peak absorbance) and 650 nm (background absorbance) by a microplate reader. Cell viability was expressed as the ratio of the absorbance of the test wells to the control wells.
[0083] MTT results are as follows Figure 6 As shown in Figure 2, the toxicity of Cel, Cel-Fe and CeFeNPs to 4T1 decreased in turn and was concentration-dependent. 3+ There was almost no effect on cell viability at this concentration.
[0084] Apoptosis reagent was used to detect the activity of CeFeNPs on breast cancer 4T1 cells. 1 mL of culture medium containing 2×105 4T1 cells was inoculated into a 12-well plate and cultured for 12 h. 0.5 µM Cel, Cel-Fe and CeFeNPs were added to the cells and cultured for 24 h. The PBS group was set as the control. After treatment, the culture medium was collected in a 1.5 mL EP tube and rinsed three times with PBS. After trypsin digestion, the cells were collected in the original culture medium, and 1 μL PI and Annexin V-FITC apoptosis detection dyes were added respectively. The cells were stained in the dark for 15 min. The flow cytometer detection results are shown as follows. Figure 7 The results were consistent with those of the MTT experiment.
[0085] Cel-Fe complex was used as a small molecule control before nanoparticle formation.
[0086] Example 4 - Comparison of the effects of CeFeNPs on the viability of 4T1 and 3T3 fibroblasts The CCK-8 method was used to detect the activity of CeFeNPs on 4T1 and 3T3. According to the different proliferation rates of the two cells, 4T1 and 3T3 cells were seeded in 96-well plates at a density of 5000 and 10000 cells per well, respectively, and cultured for 12 hours. The cells were incubated with Cel, Cel-Fe and CeFeNPs at final concentrations of 0.005, 0.05, 0.5, 5, 10, 20, and 40 µM for 24 hours. Then, 10% CCK-8 reagent diluted with RPMI 1640 (100 μL) or DMEM was added to the wells. After incubation for 4 hours at 37°C and 5% CO2, the absorbance of the wells was detected at 450 nm (peak absorbance) by an enzyme reader. Cell viability is expressed as the ratio of the absorbance of the test well and the control well. The results of 4T1 and 3T3 cell viability are shown in Figure 2. Figure 8 As shown, compared with 4T1, the toxicity of Cel-Fe and CeFeNPs to 3T3 was reduced, and the toxicity of CeFeNPs was the most obvious.
[0087] The killing effect of drugs on 4T1 and 3T3 was analyzed by flow cytometry. 4T1-GFP and 3T3-RFP cells were inoculated at 5×10 4 and 2×10 5 The cells were inoculated at a density of 100 μM in a 12-well plate and mixed cultured for 12 h. 0.5 μM Cel, Cel-Fe and CeFeNPs were added to the cells and cultured for 24 h. The PBS group was set as the control. After treatment, the culture medium was removed and the cells were washed three times with PBS. The cells were collected after trypsin digestion and the flow cytometry results were shown in Figure 2. Fig. 9 As shown, it shows that CeFeNPs have good attenuation effect and selective killing against tumor cells and normal cells (3T3).
[0088] Example 5 - Delivery effect of CeFeNPs on tumor cells Atomic absorption spectroscopy (AAS) was used to detect the intracellular iron content. 6 2mL of culture medium of 4T1 cells was inoculated into a six-well plate and cultured in an incubator for 12 hours. Cel-Fe and CeFeNPs solutions were added respectively to make the final Fe concentration 2 µM, and three culture time periods of 1 h, 4 h, and 7 h were set. Three replicate wells were set for each group, and the PBS group was set as the control. After the drug treatment was completed, the culture medium was aspirated and gently washed three times with cold PBS to ensure that the drugs that were not swallowed into the cells were washed away. The six-well plate was placed in a fume hood, and 100 µL of concentrated HNO3 and 100 µL of 30% H2O2 solution were added to each well. After 3 days of digestion, the digested liquid was collected, the volume was fixed to 2 mL, and the iron content was tested using AAS. The results are shown in Figure 2. Fig.10 As shown, the iron content of cells treated with drugs increased with the treatment time, and the iron content of the group treated with CeFeNPs was the highest.
[0089] CeFeNPs were labeled with fluorescent dye Cy5.5 NHS to detect the delivery effect on tumor cells. A drop of PBS was added to a 24-well plate and a coverslip was placed. 1 mL of 5×10 44T1 cells were cultured in a culture medium and incubated for 12 h in an incubator. CeFeNPs with an Fe concentration of 2 µM were added to the cells and cultured for 1 h, 4 h, and 7 h, respectively. After treatment, the culture medium was removed and the cells were rinsed three times with PBS. The coverslip was removed and placed on a microscope slide, stained with DAPI and mounted. CLSM images were then collected. The CLSM results are shown in Figure 2. Fig.11 As shown, red fluorescence (Cy5.5) was difficult to observe in cells treated for 1 h, a small amount of red fluorescence was observed in cells treated for 4 h, and the strongest red fluorescence was observed in cells treated for 7 h.
[0090] The above experiments prove that both Cel-Fe and CeFeNPs can be phagocytosed by tumor cells, and CeFeNPs can be phagocytosed by tumor cells more efficiently.
[0091] The preparation of CeFeNPs containing fluorescent dye Cy5.5 NHS is to add a trace amount of Cy5.5 NHS powder to the organic solvent of Cel-Fe complex and polymer, and then proceed to the next step after it is completely dissolved.
[0092] Example 6 - CeFeNPs induce ferroptosis Characterization of intracellular reactive oxygen species (ROS) using CLSM. Place a drop of PBS in a 24-well plate and place a coverslip. Add 1 mL of 5×10 4 4T1 cells were cultured in a culture medium and incubated in an incubator for 12 h. 0.5 µM Cel, Cel-Fe, and CeFeNPs were added to the cells and cultured for 24 h. The PBS group was set as the control. After treatment, the culture medium was removed and the cells were rinsed three times with PBS. Incubated with the ferroptosis probe BODIPY 581 / 591 C11 (ThermoFisher, D3861) at 37 °C for 30 min. After washing with PBS three times, the coverslip was removed and placed on a microscope slide, stained with DAPI and sealed. Images were then collected using CLSM. The CLSM results are shown in Figure 2. Fig.12 As shown, the green fluorescence in 4T1 cells treated with CeFeNPs was the strongest, indicating that the most ROS was produced and the ferroptosis effect was the strongest.
[0093] The above experiments prove that CeFeNPs can effectively induce an increase in reactive oxygen species in 4T1 cells, leading to ferroptosis.
[0094] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. It should be pointed out that for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims, and the description and drawings can be used to interpret the content of the claims.
Claims
1. A method for preparing tripterygium wilfordii nanoparticles, characterized in that: include: a) mixing a tripterygium wilfordii solution and an iron ion solution to obtain a tripterygium wilfordii-iron complex; b) mixing the tripterygium wilfordii-iron complex with a water-soluble high molecular polymer containing a dopamine group in a molar ratio of 1:(1-2) to obtain an organic phase solution; c) uniformly dispersing the organic phase solution in water to obtain a mixed solution; d) dialyzing the mixed solution and then performing solid-liquid separation to obtain a solid component.
2. The preparation method according to claim 1, characterized in that: The water-soluble high molecular polymer containing dopamine groups is methoxy polyethylene glycol dopamine.
3. The preparation method according to claim 2, characterized in that: The molecular weight of the methoxy polyethylene glycol dopamine is 2000-5000.
4. The preparation method according to claim 1, characterized in that: In step c), the volume of the water is 10-50 times; or 15-25 times that of the organic phase solution.
5. The preparation method according to claim 1, characterized in that: In step c), ultrasound and stirring are used to disperse the mixture uniformly; the ultrasound power is 60W-90W, and the ultrasound time is 1min-3min.
6. The preparation method according to any one of claims 1 to 5, characterized in that: The method further comprises the step e): freeze-drying the solid component obtained in step d).
7. Tripterygium wilfordii nanoparticles, characterized in that: The method is prepared by any one of claims 1 to 6.
8. A pharmaceutical composition, characterized in that Containing the tripterygium wilfordii nanoparticles according to claim 7 and a pharmaceutically acceptable carrier.
9. Use of the tripterygium wilfordii nanoparticles of claim 8 in the preparation of a medicament for treating tripterygium wilfordii-responsive diseases or conditions; the tripterygium wilfordii-responsive diseases or conditions include any one or more of the following: cancer, inflammatory and / or autoimmune disorders, neurological disorders, obesity-related diseases or conditions, liver-related diseases or conditions, eye disorders or injuries.
10. The use according to claim 9, characterized in that: The tripterygium wilfordii nanoparticles are combined with ATP to prepare medicine.
Citation Information
Patent Citations
Dopamine ligand-containing diblock polymer, and synthesis method and application thereof
CN110105562A
Tripterine-loaded PEGylated magnetic nanoparticles as well as preparation method and application thereof
CN117503728A
One step assembly of metal-polyphenol complexes for versatile film and particle engineering
WO2014197940A1
